Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
-
Arrowhead Pharma (ARWR) PT Raised to $80 at Cantor Fitzgerald Ahead of a Catalyst Rich 2021
-
Arrowhead Pharmaceuticals to Participate in Upcoming September 2020 Conferences
-
Arrowhead Research (ARWR) PT Raised to $55 at Cantor Fitzgerald
-
Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $266.8 Million
-
Arrowhead Pharmaceuticals Inc. (ARWR) Prices 4M Share Offering at $58/Sh
-
Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock
-
Arrowhead Pharmaceuticals Inc. (ARWR) Announces Proposed 4M Share Common Offering
-
Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock
-
Arrowhead Pharmaceuticals Corp (ARWR) May Be Worth $75-$90 in a Sale - Cantor Fitzgerald
-
Arrowhead Pharmaceuticals to Participate in Upcoming October 2019 Conferences
-
Cantor Fitzgerald Downgrades Arrowhead Research (ARWR) to Neutral
-
Arrowhead Research (ARWR) PT Raised to $24 at Cantor Fitzgerald
-
Arrowhead Pharmaceuticals to Present at Upcoming October 2018 Conferences
-
Arrowhead Research (ARWR) PT Raised to $18 at Cantor Fitzgerald
-
Cantor Fitzgerald Upgrades Arrowhead Research (ARWR) to Overweight
-
Arrowhead Research (ARWR) PT Raised to $5 at Cantor Fitzgerald Citing a Stronger Balance Sheet
-
Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $60.4 Million
-
Arrowhead Pharmaceuticals Corp (ARWR) Prices 10M Common Stock Offering at $5.25/Share
-
Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock
-
Arrowhead Pharmaceuticals Corp (ARWR) Proposed Underwritten Offering of Common Stock
-
Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock
-
Arrowhead Pharmaceuticals Corp (ARWR): Raising PT 100% After Analyst Day - Cantor
-
Arrowhead to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
-
Cantor Fitzgerald Downgrades Arrowhead Research (ARWR) to Hold
-
Cantor Fitzgerald Says Arrowhead Pharma's (ARWR) RNAi Deal with Amgen Validates Platform; Affirms at 'Buy'
-
Pre-Open Stock Movers 8/18: (SEMI) (CIE) (RPTP) Higher; (EARS) (CERU) (PTLA) Lower
-
Cantor Fitzgerald Starts Arrowhead Research (ARWR) at Buy
-
Arrowhead Pharmaceuticals Closes $45 Million Private Offering
-
Arrowhead Research (ARWR) Prices $45M Private Stock Offering at $5.90/Share
-
Arrowhead Pharmaceuticals Prices $45 Million Private Offering
-
Arrowhead Pharmaceuticals to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference

